Tech Company Financing Transactions

Savara Pharmaceuticals Funding Round

Savara Pharmaceuticals closed a $16 million Series B financing round on 3/20/2013. Investors included Central Texas Angel Network, Keiretsu Forum - Southern California and North Texas Angel Network.

Transaction Overview

Announced On
3/20/2013
Transaction Type
Venture Equity
Amount
$16,000,000
Round
Series B
Proceeds Purpose
Savara Pharmaceuticals will use the Series B funds to support a phase IIa clinical program evaluating the efficacy of AeroVancTM (vancomycin hydrochloride inhalation powder) for the treatment of pulmonary methicillin-resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis (CF) patients.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
6836 Bee Cave Rd. Building 3, 200
Austin, TX 78746
USA
Email Address
Overview
Savara is a pharmaceutical company developing novel respiratory therapeutics utilizing our proprietary NanoCluster dry powder aerosol drug delivery platform.
Profile
Savara Pharmaceuticals LinkedIn Company Profile
Social Media
Savara Pharmaceuticals Company Twitter Account
Company News
Savara Pharmaceuticals News
Facebook
Savara Pharmaceuticals on Facebook
YouTube
Savara Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Robert Neville
  Robert Neville LinkedIn Profile  Robert Neville Twitter Account  Robert Neville News  Robert Neville on Facebook
Chief Financial Officer
David Lowrance
  David Lowrance LinkedIn Profile  David Lowrance Twitter Account  David Lowrance News  David Lowrance on Facebook
Chief Operating Officer
Taneli Jouhikainen
  Taneli Jouhikainen LinkedIn Profile  Taneli Jouhikainen Twitter Account  Taneli Jouhikainen News  Taneli Jouhikainen on Facebook
VP - Bus. Development
Peter Ginsberg
  Peter Ginsberg LinkedIn Profile  Peter Ginsberg Twitter Account  Peter Ginsberg News  Peter Ginsberg on Facebook
VP - Finance
Michael Ciesla
  Michael Ciesla LinkedIn Profile  Michael Ciesla Twitter Account  Michael Ciesla News  Michael Ciesla on Facebook
VP - General Counsel
Kate McCabe
  Kate McCabe LinkedIn Profile  Kate McCabe Twitter Account  Kate McCabe News  Kate McCabe on Facebook
VP - Regulatory Affairs
Cecilia Ganslandt
  Cecilia Ganslandt LinkedIn Profile  Cecilia Ganslandt Twitter Account  Cecilia Ganslandt News  Cecilia Ganslandt on Facebook
VP - Regulatory Affairs
Mette Vinge
  Mette Vinge LinkedIn Profile  Mette Vinge Twitter Account  Mette Vinge News  Mette Vinge on Facebook


 

 

Browse more venture capital transactions:

Prev: 3/20/2013: Outbrain venture capital transaction
Next: 3/20/2013: RessQ Technologies venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to record every notable VC transaction. VC transactions reported here come from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary